Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China ; volume:22 ; number:1 ; day:8 ; month:8 ; year:2022 ; pages:1-11 ; date:12.2022
BMC infectious diseases ; 22, Heft 1 (8.8.2022), 1-11, 12.2022
- Creator
-
Zhao, Ting
Xu, Xiaolei
Wu, Yushan
Zhang, Wei
Zeng, Qin
Lu, Yanqiu
Yang, Tongtong
Zhou, Guoqiang
Yu, Jianhua
Lan, Ke
Harypursat, Vijay
Chen, Yaokai
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12879-022-07665-z
- URN
-
urn:nbn:de:101:1-2022102419374343988956
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhao, Ting
- Xu, Xiaolei
- Wu, Yushan
- Zhang, Wei
- Zeng, Qin
- Lu, Yanqiu
- Yang, Tongtong
- Zhou, Guoqiang
- Yu, Jianhua
- Lan, Ke
- Harypursat, Vijay
- Chen, Yaokai
- SpringerLink (Online service)
Other Objects (12)
A Study of Clearance of Infection in HIV-Associated Cryptococcal Meningitis after Amphotericin-Based Induction and Fluconazole-Based Consolidation Therapy
Thalidomide for Recurrence of Symptoms following HIV-Associated Cryptococcal Meningitis
High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis
HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings
HIV-associated Cryptococcal Meningitis: a Review of Novel Short-Course and Oral Therapies
Evaluation of the initial 12 months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda
The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms
Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre™ YeastOne™ YO9 platform
K21 Compound, a Potent Antifungal Agent: Implications for the Treatment of Fluconazole-Resistant HIV-Associated Candida Species
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan
High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis
A Study of Clearance of Infection in HIV-Associated Cryptococcal Meningitis after Amphotericin-Based Induction and Fluconazole-Based Consolidation Therapy
Thalidomide for Recurrence of Symptoms following HIV-Associated Cryptococcal Meningitis
High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis
HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings
HIV-associated Cryptococcal Meningitis: a Review of Novel Short-Course and Oral Therapies
Evaluation of the initial 12 months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda
The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms
Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre™ YeastOne™ YO9 platform
K21 Compound, a Potent Antifungal Agent: Implications for the Treatment of Fluconazole-Resistant HIV-Associated Candida Species
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan
High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis
A Study of Clearance of Infection in HIV-Associated Cryptococcal Meningitis after Amphotericin-Based Induction and Fluconazole-Based Consolidation Therapy
Thalidomide for Recurrence of Symptoms following HIV-Associated Cryptococcal Meningitis
High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis
HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings
HIV-associated Cryptococcal Meningitis: a Review of Novel Short-Course and Oral Therapies
Evaluation of the initial 12 months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda
The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms
Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre™ YeastOne™ YO9 platform
K21 Compound, a Potent Antifungal Agent: Implications for the Treatment of Fluconazole-Resistant HIV-Associated Candida Species
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan